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To cope with the global bacterial multidrug resistance, scientiﬁc communities have devoted
signiﬁcant efforts to develop novel antibiotics, particularly those with new modes of actions.
Teixobactin, recently isolated from uncultured bacteria, is considered as a promising ﬁrst-in-
class drug candidate for clinical development. Herein, we report its total synthesis by a highly
convergent Ser ligation approach and this strategy allows us to prepare several analogues of
the natural product.
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T
he globally ever-increasing antimicrobial resistance has
become a serious threat to human health and it demands
immediate attention to develop novel therapeutic
agents1–3. Recently, a breakthrough cyclic depsipeptide
antibiotic, teixobactin, has been discovered through screening of
uncultured bacteria4. Teixobactin exhibits excellent activities
against an array of Gram-positive pathogens, including
methicillin-resistant Staphylococcus aureus, vancomycin-
resistant Enterococcus and Mycobacterium tuberculosis. Previous
studies have shown that teixobactin binds to a highly conserved
motif of lipid II (precursor of peptidoglycan) and lipid III, which
is a precursor of the cell wall component teichoic acid, and
therefore inhibits bacterial cell wall biosynthesis. Since the
molecular target of teixobactin is not an endogenous protein,
mutant strains of Staphylococcus aureus or Mycobacterium
tuberculosis that are resistant to teixobactin have not been
obtained even after 27 days of repetitive treatments. Compared
with other lipid II inhibitors, including vancomycin, ramoplanin,
enduracidin and mannopeptimycin (Fig. 1a), teixobactin has a
comparatively less complex bioactive pharmacophore structure
(Fig. 1b). It remains to investigate how teixobactin binds to lipid
II differently from others. Nevertheless, teixobactin is a very
promising candidate for the development of new antibacterial
drugs and provides a new cyclic depsipeptide-based structural
scaffold for medicinal chemistry studies5–7.
The attractive antibacterial proﬁle of teixobactin in conjunction
with its novel structure features has enticed signiﬁcant interests for
its synthetic studies8–11. Teixobactin contains a 13-membered
depsicyclic ring motif composed of four amino acids including a
non-proteinogenic amino-acid residue, enduracididine (Fig. 1),
which is anchored with a seven-amino-acid linear chain. Herein, we
report the total synthesis of teixobactin via convergent construction.
Results
Synthesis of teixobactin. Teixobactin contains a (2S, 4S)
enduracididine (L-allo-End), an N-methyl-D-phenylalanine and
three other D-amino-acid residues. Except L-allo-End, all other
amino-acid derivatives are commercially available and the ana-
logues of teixobactin containing single-amino-acid substitution
(for example, by replacing L-allo-End with Arg) have been pre-
pared previously by solid-phase peptide synthesis8,9. It goes
without saying that the knowledge accumulated during the
analogue synthesis and biological evaluation would shed light on
the natural product; however, in reality, the fundamental
chemical reactivity, structural features and detailed biological
function of teixobactin have to be rigorously established based on
its natural form, which is the mainstay for any future medicinal
chemistry optimization. For this reason, we have recently
developed an efﬁcient synthesis of enduracididine building
block10, and have now incorporated it into the total synthesis
of teixobactin. To construct teixobactin, we adopted a convergent
strategy via Ser/Thr ligation12 by merger of the linear hexapeptide
(1–6) and the cyclic depsi-pentapeptide (7–11). Such a strategy is
highly advantageous for the divergent synthesis of teixobactin
analogues and allows expedient structure–activity relationship
studies of the pharmacophore.
We selected to perform the peptide cyclization at the least
sterically congested Thr8–Ala9 site, thus the synthesis of cyclic
peptide commenced from Thr8 (Fig. 1b). Observing that Fmoc-
Ile-OH was not readily coupled with the resin-bound Alloc-D-Thr
to form the ester linkage, depsipeptide Alloc-D-Thr-O(Fmoc-Ile)-
OH 4 was ﬁrst prepared via solution-phase coupling and then
immobilized onto the resin (Fig. 2). Alloc and Fmoc were chosen
as the orthogonal protecting groups. Alloc-D-Thr-OH was ﬁrst
protected as 4-methoxybenzyl (PMB) ester 2, which was next
coupled with Fmoc-Ile-OH to afford depsipeptide 3. After the
PMB group of 3 was removed by triﬂuoroacetic acid (TFA), the
resulting free carboxylic acid 4 was immobilized onto 2-Cl-Trt
resin to form 5. On removal of the Alloc group effected by
Pd(PPh3)4/PhSiH3, the free amino group was coupled with Boc-
Ser(OtBu)-OH under standard conditions to give resin-linked
depsi-tripeptide 6. It is noted that during these processes, O- to
N-acyl (Ile) transfer was not observed. Subsequently, the coupling
of Fmoc-End(Cbz)2-OH onto resin-linked 6 with DIC/HOBt was
very sluggish, requiring three repetitive 10-h couplings for
completion. Next, Fmoc-Ala-OH was elongated onto the resin
to afford 7, which was then cleaved from the resin under the mild
acidic conditions (TFE/AcOH/DCM) to give the side chain
protected peptide 8 for cyclization. Even though the formation of
diketopiperazine during the processes of Fmoc removal of the
End residue and the subsequent Fmoc-Ala coupling was a major
concern for the linear peptide synthesis, we were delight to ﬁnd
out that this side reaction was not observed, probably prohibited
by the bulky group. Tetrapeptides (12-member ring) have been
known to be difﬁcult for cyclization due to the constrained
geometry of the peptide backbone13. In the case of teixobactin,
the cyclization of the 13-membered depsicyclic ring proceeded
smoothly using HATU/HOAt/OxymaPure9 in CH2Cl2 at a
concentration of 0.1mM for 24 h at room temperature. The
resultant cyclic peptide was subjected to TFA treatment and
hydrogenation (Pd(OH)2, H2) to remove the Boc group and Cbz
group, respectively. After high-performance liquid
chromatography (HPLC) puriﬁcation, cyclic peptide 9 was
obtained in 17% based on the weight of the crude linear
peptide 8 obtained from SPPS.
Study on the epimerization of the cyclization. To address the
potential epimerization problem during the cyclization, we
prepared two model acyclic pentapeptides (in both cases, L-allo-
End was replaced by L-Orn) and investigated the product
stereochemistry after ring closure (Fig. 3). In the ﬁrst model
compound, D-Thr (2R, 3S) 1a was used to construct the
cyclization precursor, whereas in the second case, L-allo-Thr
(2S, 3S) 1b was employed to build the quasi-cycle. Both
compounds underwent smooth cyclization under the previously
described conditions, and the epimeric products gave distinctive
retention times when co-injected in the HPLC analysis (Fig. 3).
This observation supported that the stereochemical integrity was
retained during the preparation of depsipeptide 9.
Having completed cyclic peptide part 9, Ser ligation was then
used to complete the synthesis of teixobactin. The linear peptide
fragment containing C-terminal salicylaldehyde ester 11 was
synthesized by solid-phase peptide synthesis13. Ligation
proceeded efﬁciently to couple 9 and 11 in pyridine/AcOH (6:1,
mol:mol) with a completed HPLC conversion to afford teixobactin
12 in 37% yield after HPLC puriﬁcation (Supplementary
Methods). The general applicability and robustness of this
strategy was further demonstrated by the synthesis of several
analogues 13–16. By replacing L-allo-End, D-Thr and D-allo-Ile,
analogues 13 (D-allo-Ile5D-Ile), 14 (D-allo-Ile5D-Ile, End10Arg), 15
(D-allo-Ile5D-Ile, D-Thr8Thr, End10Arg) and 16 (End10Orn) were
prepared accordingly. It was noted that the solid-phase peptide
synthesis of the End10Arg and End10Orn analogues was much
smoother than that of teixobactin, leading to 30% and 50% yields
(based on the weight of the crude peptide obtained from SPPS),
respectively, after cyclization. This observation suggests that the
synthesis of teixobactin in its natural form is likely to come across a
distinct set of challenges compared with the analogue synthesis;
and the natural product should be the rational starting point for
future chemical and biological optimization.
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Antibacterial studies. Synthetic teixobactin and its analogues were
subjected to the assessment of their antimicrobial activities by
determining their minimal inhibitory concentration on various
Gram-positive bacteria strains including methicillin-susceptible
S. aureus strain ATCC29213 and methicillin-resistant S. aureus
clinical isolates. Our data indicated that the synthetic texobactin
exhibited similar activity as the natural teixobactin, as reported
previously (Table 1) and the analogues with different stereo-con-
ﬁguration at D-allo-Ile exhibited reduced activity towards different
Gram-positive bacterial pathogens. L-allo-End is important for the
potent antibacterial activity of teixobactin, as its replacement with
Orn (16) or Arg14 caused reduced antibacterial activities. These
studies suggested that superior teixobactin analogues should
maintain the L-allo-End-cyclic peptide fragment and examine the
variation of the seven-amino-acid linear chain fragment. In this
effort, the original stereo-conﬁguration of the amino-acid residue
should be thoroughly scrutinized. From our study, it is encouraging
to ﬁnd that Orn-containing teixobactin analogues maintained
modest antibacterial activity. Since Orn is readily available as
compared with L-allo-End and the synthesis of the Orn-containing
cyclic depsipeptide (7–11) gave the best yield among all the
analogue syntheses, which is amenable to a large-scale synthesis.
Through the above-developed convergent synthetic strategy,
various linear hexapeptide (1–6), such as 11, can be readily
prepared and ligated to the Orn-containing the cyclic
depsi-pentapeptide (7–11) to investigate the contribution of each
amino acid in the linear peptide fragment towards the antibacterial
activity, which will lead to the optimal structure for the
development of teixobactin with improved properties.
Discussion
In summary, we have developed the total synthesis of texobactin
featuring a ligation-mediated convergent 6þ 5 strategy, which
aims to provide a combinatory approach for the synthesis of its
analogues to establish a comprehensive structure–activity rela-
tionship and facilitate future search for analogues with improved
pharmacological properties. Our preliminary structure-activity
relationship (SAR) studies suggested that replacing of difﬁcultly
obtained End with readily available Orn could maintains a
modest antibacterial activity, which provides alternative structural
motif for its medicinal chemistry studies.
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Figure 1 | The structures of some cyclic peptide-based lipid II inhibitors. (a) Enduracidins A and B were discovered in late 1960s by Nakazawa and
Mizuno et al14,15. The structure of Ramoplanin was established in 1989 by Cavalleri et al16. Mannopeptimycin was isolated in 1950s and ﬁrst elucidated
around 2002 (ref. 17). (b) Teixobactin was discovered in 2015 as a new lipid II inhibitor4. Our synthetic disconnection of teixobactin was also described.
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Methods
General. For nuclear magnetic resonance (NMR) data and mass spectra of the
compounds in this article, see Supplementary Figs 1–43, and Supplementary
Tables 1 and 2. High-resolution mass spectra were recorded on a quadrupole-time-
of-ﬂight mass spectrometer. Accurate masses are reported for the molecular ion
[MþH]þor a suitable fragment ion. NMR spectra were recorded at room tem-
perature on a 400-MHz NMR spectrometer or Bruker Avance 600 FT-NMR
spectrometer at 600MHz.
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Figure 2 | Synthetic route towards teixobactin. Peptides 9 and 11 were prepared by SPPS and coupled through Ser ligation, which was developed in our group.
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Convergent synthesis of teixobactin and its analogues via serine/threonine
ligation. The peptide salicylaldehyde ester (1.5 equiv.) and the cyclic peptide
fragment (1.0 equiv.) were dissolved in pyridine/AcOH buffer (6:1, mol:mol). The
reaction was monitored by HPLC mass spectrometer until the reaction was
completed, followed by acidic cleavage of N,O-benzylidene acetal intermediate by
TFA cocktail (TFA/H2O/TIPS, 95:2.5:2.5, v-v:v). The residue was puriﬁed by
preparative HPLC.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the article (and its Supplementary Information ﬁles).
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